


Complexo de
Histocompatibilidade
Principal: Estrutura,
Função, Apresentação
de Antígenos e
Implicações Clínicas




# Reconhecimento Antigênico pela Célula B



# Reconhecimento Antigênico pelas Células T




#### Localização no Genoma




Klein J, Sato A. The HLA System. First of two parts. N Engl J Med 2000;343:702-9.




#### Locus dos Genes do MHC




## Estrutura do MHC




# Molécula Classe I








Fenda Fechada




# Estrutura da molécula de MHC classe I









#### Ligação do peptídeo à molécula de MHC classe I









Ligam ~ 2000 peptídeos 10<sup>5</sup> de cada variante alélica por célula


apresentação ~ 100-4000 cópias

8-10 aa

# Molécula Classe II










**Fenda Aberta** 


#### Estrutura da molécula de MHC classe II



#### Ligação do peptídeo à molécula de MHC classe II









# O Acomodamento do Antígeno na Fenda


MHC Classe I

MHC Classe II





#### Prêmio Nobel de Medicina e Fisiologia 1980



George Snell Estados Unidos




Jean Dausset França



Baruj Benacerraf Venezuela


# Co-dominância dos Genes do MHC



# Como se dá o processamento e a apresentação do antígeno?




#### **Antigen Processing, Panel A**



Klein J, Sato A. The HLA System. First of two parts. N Engl J Med 2000;343:702-9.





# Degradação de substâncias presentes no citosol








TAP





















#### **Antigen Processing, Panel B**




Klein J, Sato A. The HLA System. First of two parts. N Engl J Med 2000;343:702-9.





## Síntese da molécula de classe II do MHC






# Síntese da molécula de classe II do MHC







## Degradação da cadeia invariante



# Apresentação do peptídeo na superfície celular



# Formação do Complexo MHC - Ag - TCR




# Macrophage

Endoplasmic reticulum




# Interação APC + Célula T



Medzhitov R, Janeway C Jr. Innate Immunity. N Engl J Med 2000;343:338-44.




# 1 APC Vs. Várias Células T




#### IMPORTANTE

- · MHC I é encontrado em todas as células nucleadas
- · MHC II é encontrado em células do sistema imune
  - Linfócitos T CD4 Humanos expressam MHC II
- MHC I apresenta antígenos para células T CD8 (citotóxicas)]
- MHC II apresenta antígenos para células T CD4 (auxiliares)











## Outras Moléculas




## Moléculas de Adesão e Integrinas






### Ativação ou Desativação ?





A apresentação de antígenos associada à presença ou não de moléculas co-estimulatórias ou inibitórias regem a ativação das células T

## Sinais para a ativação dos linfócitos T




# APC: moléculas co-estimuladoras e seus ligantes






Célula dendrítica



Macrófago




Linfócito B





MHC+peptideo


MHC+peptideo+B7




# Sinalização intracelular durante a ativação dos linfócitos T





















# Sinalização intracelular durante a ativação dos linfócitos T

























## Proliferação e diferenciação dos linfócitos T






Célula T de memória



Célula T efetora


## Respostas efetoras mediadas por células T



# Por quê Complexo Principal de Histocompatibilidade ?



# Por quê Complexo Principal de Histocompatibilidade?



enxerto isogênico

enxerto alogênico

enxerto xenogênico

enxerto congênico

### Qual a Relação entre HLA e Doenças Autoimunes ?




Associations of HLA genotype with susceptibility to autoimmune disease								
Disease	HLA allele	Relative risk	Sex ratio (♀:♂)					
Ankylosing spondylitis	B27	87.4	0.3					
Acute anterior uveitis	B27	10.04	<0.5					
Goodpasture's syndrome	DR2	15.9	7					
Multiple sclerosis	DR2	4.8	10					
Graves' disease	DR3	3.7	4–5					
Myasthenia gravis	DR3	25	7					
Systemic lupus erythematosus	DR3	5.8	10-20					
Insulin-dependent diabetes mellitus	DR3 and DR4	3.2	7					
Rheumatoid arthritis	DR4	4.2	3					
Pemphigus vulgaris	DR4	14.4	~1					
Hashimoto's thyroiditis © 1997 Current Biology Ltd. / Garland P	DR5	3.2	4-5					

<sup>© 1997</sup> Current Biology Ltd. / Garland Publishing, Inc.

## Espondilite Anquilosante

- ·HLA-B27
- ·Inflamação crônica da medula espinhal e articuações
- ·Resposta auto-imune
- •Outros genes ARTS 1 e IL-23r





# Associação entre infecções e doenças auto-imunes

Associations of infection with immune-mediated tissue damage							
Infection	HLA association	Consequence					
Group A Streptococcus	?	Rheumatic fever (carditis, polyarthritis)					
Chlamydia trachomatis	HLA-B27	Reiter's syndrome (arthritis)					
Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Yersinia enterocolitica, Campylobacter jejuni	HLA-B27	Reactive arthritis					
Borrelia burgdorferi	HLA-DR2, DR4	Chronic arthritis in Lyme disease					

@ 1997 Current Biology Ltd. / Garland Publishing, Inc.


#### Especificidades HLA detectadas sorologicamente

	classe I			classe II			
locos	Α	В		- C	DR	DQ	DP
antígenos	1 2 3 9 10 11 w19 23 24 25 26 28 29 30 31 32 w33 w34 w36 w43 w66 w68 w68 w68	5 7 8 12 13 14 15 16 17 18 21 w22 27 35 37 38 39 40 w41 w42 44 45 w46 w47 w48	w50 51 w52 w53 w54 w55 w56 w57 w58 w59 w60 w61 w62 w63 w64 w65 w70 w71 w72 w73 w75 w76 w4	w1 w2 w3 w4 w5 w6 w7 w8 w9 w10 w11	1 2 3 4 5 w6 7 w8 w9 w10 w11 w12 w13 w14 w15 w16 w17 w18 w52 w53	w1 w2 w3 w4 w5 w6 w7 w8 w9	w1 w2 w3 w4 w5 w6

Será por isso que é tão difícil desenvolvermos vacinas?


Imunodominância

#### Mecanismos Centrais de Tolerância




Comprometimento na Apresentação do Antígeno, Possibilita o Escape de Células Auto-reativas - Ativação na Periferia

#### Células com Baixa Expressão de MHC I São Alvos de Lise por Células NK



#### Alguns Patógenos Apresentam Moléculas Chamadas Superantígenos - Ativação Policlinal



#### Resumindo

- MHC I e II codificam moléculas de superfície capazes de apresentar Ags para CD8 e CD4 respectivamente,
- HLA A,B,C (Classe I) HLA-DP, DQ DR (Classe II)
- Importantes na apresentação de Ag
- · Geração de Tolerância
- · Relação com Doenças Auto-imunes.